Table 1.
Characteristics of the 1830 studied patients and the general population from Veneto
| Variable | Study population (n = 1830) | General population from Veneto (n = 4,905,854) |
|---|---|---|
| Age, years (mean ± SD) | 55 ± 14.8 | 45.1 ± 23.4 |
| Male gender, n (%) | 1208 (66) | 2,399,783 (48.9) |
| Presence of psoriatic arthritis, n (%) | 606 (33.1) | |
| Biologic therapy used | ||
| TNF inhibitor | 1112 (55.3) | |
| IL-17 inhibitor | 527 (28.8) | |
| IL-12/IL-23 or IL-23 inhibitor | 291 (15.9) | |
| Presence of obesity, n (%) | 512 (27.9) | 495,491 (10.1) |
| Presence of hypertension, n (%) | 474 (25.9) | 833,995 (17.0) |
| Presence of cardiovascular disease, n (%) | 223 (12.2) | 210,952 (4.3) |
| Presence of diabetes, n (%) | 252 (13.8) | 220,763 (4.5) |
| COVID-19 incidence rate per 10,000 person-months (95% CI) | 9.7 (3.9–20.1) | 11.5 (11.4–11.7) |
| COVID-19-related hospitalizations per 10,000 person-months (95% CI) | 4 (2.0–15.6) | 9.6 (9.4–9.7) |
| COVID-19-related deaths per 10,000 person-months (95% CI) | 0 (0–10.4) | 1.16 (1.10–1.21) |
CI confidence interval, IL interleukin, SD standard deviation, TNF tumor necrosis factor